HPC
DNLI icon

HM Payson & Co’s Denali Therapeutics DNLI Stock Holding History

HM Payson & Co’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.14K Buy
+200
New +$4.11K ﹤0.01% 980
2022
Q1 		– Sell
-578
Closed -$26K – 1073
2021
Q4 		$26K Buy
+578
New +$27.4K ﹤0.01% 716
2021
Q2 		– Sell
-1,013
Closed -$58K – 1102
2021
Q1 		$58K Hold
1,013
– – ﹤0.01% 575
2020
Q4 		$85K Sell
1,013
-237
-19% -$14.3K ﹤0.01% 500
2020
Q3 		$45K Buy
+1,250
New +$37.6K ﹤0.01% 581

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HM Payson & Co's DNLI Position: Q2 2026 in Review

HM Payson & Co opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 200 shares worth $5.14K. The stake represents ﹤0.01% of the portfolio and ranks #980 among its holdings. This is a return to the name: HM Payson & Co previously reported a position in DNLI as recently as Q4 2021.

HM Payson & Co first reported a position in DNLI in Q3 2020 and has held it in 5 quarters since. The position peaked at $85K in Q4 2020. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • HM Payson & Co held 200 shares of Denali Therapeutics worth $5.14K as of Q2 2026.
  • Denali Therapeutics was a new HM Payson & Co position in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of HM Payson & Co's portfolio in Q2 2026, its #980 holding.
  • HM Payson & Co first reported a position in Denali Therapeutics in Q3 2020 and has held it in 5 quarters since.
  • HM Payson & Co's Denali Therapeutics position peaked at $85K in Q4 2020.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.